EPGL
CRSP icon

Evelyn Partners Group Ltd’s CRISPR Therapeutics CRSP Stock Holding History

Evelyn Partners Group Ltd’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.9K Buy
+1,300
New +$68.5K ﹤0.01% 343

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Evelyn Partners Group Ltd's CRSP Position: Q2 2026 in Review

Evelyn Partners Group Ltd opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 1,300 shares worth $70.9K. The stake represents ﹤0.01% of the portfolio and ranks #343 among its holdings.

252 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Evelyn Partners Group Ltd held 1,300 shares of CRISPR Therapeutics worth $70.9K as of Q2 2026.
  • CRISPR Therapeutics was a new Evelyn Partners Group Ltd position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Evelyn Partners Group Ltd's portfolio in Q2 2026, its #343 holding.
  • 252 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Evelyn Partners Group Ltd's 13F filing for Q2 2026, filed 7 Aug 2026.